




RealRate

PHARMACEUTICAL 2021

Arcus Biosciences Inc.
Rank 157 of 402





RealRate

PHARMACEUTICAL 2021

Arcus Biosciences Inc.
Rank 157 of 402



The relative strengths and weaknesses of Arcus Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arcus Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 69% points. The greatest weakness of Arcus Biosciences Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is 142%, being 95% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	735,815
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	121,669
Liabilities, Non-Current	148,319
Other Assets	25,670
Other Compr. Net Income	-20
Other Expenses	0
Other Liabilities	0
Other Net Income	1,377
Other Revenues	77,517
Property and Equipment	10,807
Research and Development	159,348
Selling, General and Administrative Expense	42,404

Output Variable	Value in 1000 USD
Assets	772,292
Liabilities	269,988
Expenses	201,752
Revenues	77,517
Stockholders Equity	502,304
Net Income	-122,858
Comprehensive Net Income	-122,868
Economic Capital Ratio	142%